期刊文献+

骨保护素和核因子κB受体活化因子配基对体外培养鸭破骨细胞的影响

Influnce of OPG and RANKL on duck′s osteoclasts formation and activation in vitro
下载PDF
导出
摘要 探讨了核因子κB受体活化因子配基(Receptor activator of NF-κB ligand,RANKL)和不同浓度骨保护素(Os-teoprotegerin,OPG)对鸭破骨细胞(Osteoclasts,OC)生成和活化的影响。从7日龄内番鸭长骨骨髓分离破骨细胞,添加1,25-(OH)2D3进行诱导培养15 h后,更换含不同细胞因子的培养液(对照组:不加细胞因子;30μg/LsRANKL组;30μg/L sRANKL+10μg/L OPG组;10μg/L OPG组;50μg/L OPG组;100μg/L OPG组),继续培养。倒置显微镜进行OC形态学观察,比较各组培养3 d后抗酒石酸酸性磷酸酶(TRAP)阳性OC数量、培养7 d后扫描电镜观察象牙片吸收陷窝。结果表明:50μg/L OPG组、100μg/L OPG组OC数均极显著少于10μg/LOPG组(P<0.01);添加OPG组OC数均极显著少于30μg/L sRANKL组(P<0.01),象牙片吸收陷窝随OPG添加浓度的增加而减少,面积减小,陷窝深度变浅。RANKL能够促进OC的生成及活化,而OPG可与RANKL竞争性地结合RANK抑制OC的生成和活化,从而抑制OC的骨吸收。 The influnce of receptor activator of NF-κB ligand (RANKL) and different concentration of osteoprotegerin (OPG) on differentiation and activity of duck's osteoclasts was explored in the present experiment. Osteoclasts (OC) were isolated from long bone marrow of 1 to 7 days old'ducks, and supplemented with 30 ng/ml sRANKL,30 μg/L sRANKL+10 μg/L OPG, 10 μg/L OPG, 50 μg/L OPG and 100 μg/L OPG, respectively. The control group was supplemented nothing except a-MEM. The formation and activation of osteoclasts were detected (or examined) by ways of morphologic observation, histochemical staining for tartrate-resistant acid .phosphatase (TRAP) at the 3rd day and detection of lacunar resorption through scanning electron micrograph at the 7th day. Compared with groups supplemented with OPG, the number of TRAP positive osteoclasts in 30 μg/L sRANKL group increased very significantly (P〈0.01). Compared with the 10 μg/L OPG group, the number of TRAP positive osteoclasts in 50 μg/L OPG and 100 μg/L OPG group decreased very significantly (P〈0.01). The number and area of lacunar resorption decreased with concentration increasing of OPG. RANKL may advance OC formation and activation,while OPG may inhibits bone absorbing activity by inhib.iting the formation and activation of OC in vitro.
出处 《中国兽医学报》 CAS CSCD 北大核心 2009年第1期82-85,共4页 Chinese Journal of Veterinary Science
基金 国家自然科学基金资助项目(30270993) 江苏省高校自然科学研究指导性计划项目(05KJD230074) 江苏省高校“青蓝工程”培养对象资助项目(2005年) 泰州市“311工程”培养对象资助项目(2007年) 江苏畜牧兽医职业技术学院资助项目(200503)
关键词 破骨细胞 骨保护素 核因子ΚB受体活化因子配体 抗酒石酸酸性磷酸酶 骨吸收陷窝 osteoclast osteoprotegerin receptor activator of NF-κB tartrate-resistant acid phosphatase lacunar resorption
  • 相关文献

参考文献15

  • 1Tsuda E,Goto M,Monochizuki SI. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoelastogenesis [J]. J Biochem Biophysl Res Commun, 1997,234,137- 142.
  • 2Simonet WS, Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [J]. Cell, 1997,89:309-319.
  • 3Mizuno A, Amizuka N, Irie K. Severe ostoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin [J]. Bioehem Biophys Res Commun,1998,247:610-615.
  • 4Kong Y Y,Yoshida H,Sarosi I. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis [J]. Nature,1999,397 (6717) :315-323.
  • 5Theoleyre S, Wittrant Y, Tat S K, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiologieal bone remodeling [J]. Cytokine Growth Factor Reviews, 2004,15 : 457-475.
  • 6屈会起,邱明才.骨保护素的研究进展[J].国外医学(内科学分册),2000,27(8):345-347. 被引量:9
  • 7Roodman G D. Cell biology of the osteoelast [J]. J Exp Hematol, 1999,27 : 1229-1241.
  • 8Owens J M,Gallagher A C,Chambers T J. Bone Cells Required for Osteoclastic Resorption but Not for Osteoelastie Differentiation [J]. Biochem Biophys Res Commun, 1996,222 (2):225-229.
  • 9Takahashi N,Udagawa N, Suda T. A New member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/ RANKL, regulates osteoclast differentiation and function [J]. Biocbem Biophys Res Commun,1999,256(3) :449-455.
  • 10Horowitz MC, Xi YG, Wilson K, Kacena MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands [J]. Cytokine Growth Faetor Revi, 2001,12 : 9-18.

二级参考文献38

  • 1Roodman GD. Endocr Rev, 1995, 17 (4): 308-332.
  • 2Takahashi N, Akatsu T, Udagawa N, et al. Endocrinology,1988, 123 (5) :2600-2602.
  • 3Simonet WS, Lacey DL, Dunstsn CR, et al. Cell, 1997,89 (2) : 309-319.
  • 4Tan KB, Harrop J, Reddy M, et al. Gene, 1997, 204 (1-2) :35-46.
  • 5Yasuda H, Shima N, Nakagawa N, et al. Endocrinology,1998, 139 (3) : 1329-1337.
  • 6Lacey DL, Timms E, Tan HI., et al. Cell, 1998, 93 (2):165-176.
  • 7Anderson MA, Maraskovsky E, Billingsley WL, et al. Nature, 1997, 310 (6656) : 175-179.
  • 8Hoibauer LC, Gori F, Riggs BL. Endocrinology, 1999,140 (10) :4382-4389.
  • 9Hoibauer LC, Khosla S, Dunstan CR, et al. Endocrinology, 1999, 140(9):4367-4370.
  • 10Srivastava S, Torn/do G, Weitzmann MN, et al. J Biol Chem, 2001, 276 (12) : 8836-8840.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部